Atossa Therapeutics, Inc.’s Post

Why does an $850 billion pharma company obtain only 50 patents per year? Steve Caltrider - Chief IP Counsel at Dana-Farber Cancer Institute & Chair of ABA Section of Intellectual Property Law - shares  the story of why and how he relied on data to reduce Eli Lilly’s patent portfolio, and explains why obtaining less patents is likely the better strategy for many large companies. He also discusses the critical role of IP in getting medical innovations to patients, the potentially catastrophic impact of the administration’s march-in proposal, and why all patent attorneys should pay attention to patent policy developments. A must-listen for anyone interested in patent strategy, the potential impact of the administration's recent string of patent-related proposals, or how to succeed as in-house or outside counsel.

Originally published by IPWatchdog, Inc, number 6 on our continued countdown of the top ten most read articles authored by Rothwell Figg and published on JD Supra in 2023 is written by partner Dan Shores. Substantial patent litigation activity occurred in the mRNA space in 2022 and involved nearly all of the major mRNA and lipid nanoparticle (LNP) pioneers. Dan's article provides an overview of the activity as well as a summary exposure analysis. #mRNA #mRNAlitigation #mRNAIP #patentlitigation Read the article in full: https://lnkd.in/eHFkF396

Hold that Terminal Disclaimer! The same Federal Circuit panel who took away patent term adjustment (PTA) in Cellect has given it back for "first-filed, first-issued" patents--or at least shielded them from obviousness-type double patenting (OTDP) rejections over later-filed, later-issued patents that have the same priority date. This ruling preserves the ability to benefit from the "congressionally guaranteed patent term" associated with PTA in a "first" patent, and is good news for patent owners. Just make sure you've had your coffee before you try to follow how the opinion reconciles its holding with Cellect, Gilead, and other recent OTDP decisions. #patents #pharmapatents #patentlitigation

Hold that Terminal Disclaimer! The same Federal Circuit panel who took away patent term adjustment (PTA) in Cellect has given it back for "first-filed, first-issued" patents--or at least shielded them from obviousness-type double patenting (OTDP) rejections over later-filed, later-issued patents that have the same priority date. This ruling preserves the ability to benefit from the "congressionally guaranteed patent term" associated with PTA in a "first" patent, and is good news for patent owners. Just make sure you've had your coffee before you try to follow how the opinion reconciles its holding with Cellect, Gilead, and other recent OTDP decisions. #patents #pharmapatents #patentlitigation

Lots of interesting data in this recent USPTO study which support the finding "that patent expiration dates, like the number of patents, may not be predictive of the timing of actual launch of competing products" and "timing of the entry of generic products is not fully reflected by a computation of patents and exclusivities and competition could be affected by other factors." https://lnkd.in/gm7NHq4d

Thoughts on this? >> Intellia to respond to lawsuit over in vivo therapy patents >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #healthcare #biotech

It was an honor to speak on the importance of patent reform, specifically our support at Generation Patient of Senator Welch, Klobuchar, and Braun's bipartisan legislation to address patent thickets on Capitol Hill yesterday. Patent thickets are when companies file a web of additional patents beyond the primary patent, which prevents competition, discourages innovation, and keeps drug prices high. This legislation is a crucial start to protecting innovation while ensuring timely access to biosimilars and generics. You can learn more about the legislation here: https://lnkd.in/ga4vmfvu ... As young adult patients, our ability to thrive into adulthood depends on whether we can afford life-saving medicines. This legislation addressing patent thickets is crucial to ensuring timely access to biosimilars and generics. All patients should have access to medicines, not just those who can afford them. We at Generation Patient are proud to endorse this legislation, impacting the current generation and the next generation of patients.

💖 Do you love antibody patents as much as me? 💵 Are you developing an antibody asset that could be worth $billions? 🚑 Have you recently received an antibody claim rejection that was not your fault? You're in luck. Join me and my excellent colleagues Sarah Lau and Amy Nick on Thursday 23 May 2024 at 4pm (UK) for a must-see webinar on the topic of "Antibody Patents: How to best capture and protect your commercial products". I know - another antibody webinar from some EP attorneys! This one will be worth it. Click below for more information and to register.

FDA Rethinking Automatic 30-Month Stay in Patent Thickets After Endo Sues: A new chapter emerged this week in the contentious issue of patent thickets, a web of overlapping patents filed on a single existing product to create barriers to competition and extend effective patent life. #fda #financial #lifesciences

Why don't Big Pharma companies ever reach the same valuation as tech companies?? This is why. (Below). Microsoft will pretty much have the patent on Windows until the end of time. That's not how it works with medical patents. They expire within a decade (give or take 5 years) It's not only great for patients, but guess what?? Also great for shareholders. Because it forces a culture of innovation, forcing companies to methodically create new products to move medical cures forward, but also to move their profits forward. Microsoft's evergreen stock market valuation (pun intended) is actually a huge outlier. Companies like Kodak and Kmart are much more than norm... Companies that dominated for decades but then just sort of lost it even though their intellectual property never expired. There's a reason why companies like Johnson and Johnson and Pfizer have been around since the 1850s. Creative destruction is in their DNA; in the long run it's a great thing